Vivo Capital’s ALX Oncology ALXO Stock Holding History

Vivo Capital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.59M	Hold	3,184,713	–	–	0.6%	36
2026 Q1	$6.39M	Buy	+3,184,713	New	+$6.07M	0.53%	35
2024 Q4	–	Sell	-4,034,522	Closed	-$7.34M	–	42
2024 Q3	$7.34M	Sell	4,034,522 -185,526	-4%	-$690K	0.61%	27
2024 Q2	$25.4M	Hold	4,220,048	–	–	2.35%	9
2024 Q1	$47.1M	Hold	4,220,048	–	–	3.7%	7
2023 Q4	$62.8M	Hold	4,220,048	–	–	5.14%	5
2023 Q3	$20.3M	Hold	4,220,048	–	–	2.22%	14
2023 Q2	$31.7M	Hold	4,220,048	–	–	2.19%	11
2023 Q1	$19.1M	Hold	4,220,048	–	–	1.32%	16
2022 Q4	$47.6M	Hold	4,220,048	–	–	5.48%	4
2022 Q3	$40.4M	Hold	4,220,048	–	–	4.46%	5
2022 Q2	$34.1M	Hold	4,220,048	–	–	3.43%	6
2022 Q1	$71.3M	Hold	4,220,048	–	–	4.91%	6
2021 Q4	$90.7M	Hold	4,220,048	–	–	5.47%	5
2021 Q3	$312M	Hold	4,220,048	–	–	14%	1
2021 Q2	$231M	Hold	4,220,048	–	–	9.99%	2
2021 Q1	$311M	Hold	4,220,048	–	–	10.94%	2
2020 Q4	$364M	Hold	4,220,048	–	–	16.23%	1
2020 Q3	$159M	Buy	+4,220,048	New	+$166M	9.2%	2

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vivo Capital's ALXO Position: Q2 2026 in Review

Vivo Capital held its ALX Oncology (ALXO) position steady in Q2 2026 at 3,184,713 shares worth $6.59M. The position accounts for 0.6% of the portfolio, ranked #36.

Vivo Capital first reported a position in ALXO in Q3 2020 and has held it in 19 quarters since. The position peaked at $364M in Q4 2020. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Vivo Capital held 3,184,713 shares of ALX Oncology worth $6.59M as of Q2 2026.
Vivo Capital left its ALX Oncology share count unchanged in Q2 2026.
ALX Oncology made up 0.6% of Vivo Capital's portfolio in Q2 2026, its #36 holding.
Vivo Capital first reported a position in ALX Oncology in Q3 2020 and has held it in 19 quarters since.
Vivo Capital's ALX Oncology position peaked at $364M in Q4 2020.
93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.